Abbonarsi

Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial - 28/04/22

Doi : 10.1016/j.ahj.2022.01.017 
Mandeep S. Sidhu, MD a, , Karen P. Alexander, MD b, Zhen Huang, MS b, Sean M. O'Brien, PhD b, Bernard R. Chaitman, MD c, Gregg W. Stone, MD d, Jonathan D. Newman, MD, MPH e, William E. Boden, MD f, Aldo P. Maggioni, MD g, Philippe Gabriel Steg, MD h, Thomas B. Ferguson, MD i, Marcin Demkow, MD j, Jesus Peteiro, MD k, Gurpreet S. Wander, DM l, Denis C. Phaneuf, MD m, Mark A. De Belder, MD n, Rolf Doerr, MD o, Erick Alexanderson-Rosas, MD p, Carisi A. Polanczyk, MD, ScD q, Peter A. Henriksen, MBChB, PhD r, Dwayne S.G. Conway, MD s, Vicente Miro, MD, PhD t, Tali Sharir, MD u, Renato D. Lopes, MD, PhD b, James K. Min, MD v, Daniel S. Berman, MD w, Frank W. Rockhold, PhD b, Stephen Balter, PhD x, David Borrego, PhD y, Yves D. Rosenberg, MD, MPH z, Sripal Bangalore, MD, MHA e, Harmony R. Reynolds, MD e, Judith S. Hochman, MD e, David J. Maron, MD aa
on behalf of the

ISCHEMIA Research Group

a Albany Medical College, Albany, NY 
b Duke Clinical Research Institute - Duke University Medical Center, Durham, NC 
c St Louis University School of Medicine Center for Comprehensive Cardiovascular Care, St. Louis, MO 
d Icahn School of Medicine at Mount Sinai, Cardiovascular Research Foundation, New York, NY 
e NYU Grossman School of Medicine, New York, NY 
f VA New England Healthcare System, Boston University School of Medicine, Boston, MA 
g ANMCO Research Center, Florence, Italy 
h Université de Paris, Assistance Publique-Hôpitaux de Paris, INSERM-1148, Paris, France 
i Brody School of Medicine, East Carolina University, Greenville, NC, USA 
j Dept of Coronary and Structural Heart Diseases, National Institute of Cardiology, Warsaw, Poland 
k CHUAC, Universidad de A Coruña, CIBER-CV, A Coruña, Spain 
l Dayanand Medical College & Hospital, Ludhiana, Punjab, India 
m Hôpital Pierre-Le Gardeur, Quebec, Terrebonne, Canada 
n Barts Health NHS Trust, London, United Kingdom 
o Praxisklinik Herz und Gefaesse, Dresden, Germany 
p Instituto Nacional de Cardiología “Ignacio Chávez”, Mexico City, Mexico 
q Federal University of Rio Grande do Sul, Hospital Clínicas de Porto Alegre, Porto Alegre, Brazil 
r Edinburgh Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom 
s Northern General Hospital, Sheffield, United Kingdom 
t Hospital universitario y politecnico La Fe, Valencia, Spain 
u Assuta Medical Center and Ben Gurion University of the Negev, Tel Aviv, Israel 
v Cleerly, Inc. New York, NY 
w Cedars-Sinai Medical Center, Los Angeles, CA 
x Columbia University, New York, NY 
y Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 
z National Institute of Health- NHLBI, Bethesda, MD 
aa Department of Medicine, Stanford University School of Medicine, Stanford, CA 

Reprint requests: Mandeep S. Sidhu, MD, FACC, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208.Albany Medical College,47 New Scotland AvenueAlbanyNY12208

Riassunto

Background

The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches trial demonstrated no overall difference in the composite primary endpoint and the secondary endpoints of cardiovascular (CV) death/myocardial infarction or all-cause mortality between an initial invasive or conservative strategy among participants with chronic coronary disease and moderate or severe myocardial ischemia. Detailed cause-specific death analyses have not been reported.

Methods

We compared overall and cause-specific death rates by treatment group using Cox models with adjustment for pre-specified baseline covariates. Cause of death was adjudicated by an independent Clinical Events Committee as CV, non-CV, and undetermined. We evaluated the association of risk factors and treatment strategy with cause of death.

Results

Four-year cumulative incidence rates for CV death were similar between invasive and conservative strategies (2.6% vs 3.0%; hazard ratio [HR] 0.98; 95% CI [0.70-1.38]), but non-CV death rates were higher in the invasive strategy (3.3% vs 2.1%; HR 1.45 [1.00-2.09]). Overall, 13% of deaths were attributed to undetermined causes (38/289). Fewer undetermined deaths (0.6% vs 1.3%; HR 0.48 [0.24-0.95]) and more malignancy deaths (2.0% vs 0.8%; HR 2.11 [1.23-3.60]) occurred in the invasive strategy than in the conservative strategy.

Conclusions

In International Study of Comparative Health Effectiveness with Medical and Invasive Approaches, all-cause and CV death rates were similar between treatment strategies. The observation of fewer undetermined deaths and more malignancy deaths in the invasive strategy remains unexplained. These findings should be interpreted with caution in the context of prior studies and the overall trial results.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2022  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 248

P. 72-83 - Giugno 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Distinct triglyceride-glucose trajectories are associated with different risks of incident cardiovascular disease in normal-weight adults
  • Xue Tian, Yingting Zuo, Shuohua Chen, Xia Meng, Pan Chen, Yongjun Wang, Shouling Wu, Yanxia Luo, Anxin Wang
| Articolo seguente Articolo seguente
  • Prognostic value of echocardiography for heart failure and death in adults with chronic kidney disease
  • Jesse K. Fitzpatrick, Andrew P. Ambrosy, Rishi V. Parikh, Thida C. Tan, Nisha Bansal, Alan S. Go, CRIC Study Investigators,

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.